PharmGKB summary: very important pharmacogene information for CYP3A5.
作者信息
Lamba Jatinder, Hebert Joan M, Schuetz Erin G, Klein Teri E, Altman Russ B
机构信息
Department of Experimental and Clinical Pharmacology, College of Pharmacy, Institute of Human Genetics, University of Minnesota, Minnesota, USA.
出版信息
Pharmacogenet Genomics. 2012 Jul;22(7):555-8. doi: 10.1097/FPC.0b013e328351d47f.
Abstract
摘要
相似文献
1
PharmGKB summary: very important pharmacogene information for CYP3A5.药物基因组知识库总结：关于CYP3A5的非常重要的药物基因信息。
Pharmacogenet Genomics. 2012 Jul;22(7):555-8. doi: 10.1097/FPC.0b013e328351d47f.
2
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.临床药物基因组学实施联盟（CPIC）关于CYP3A5基因分型与他克莫司给药的指南。
Clin Pharmacol Ther. 2015 Jul;98(1):19-24. doi: 10.1002/cpt.113. Epub 2015 Jun 3.
3
CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.CYP3A药物遗传学与成人心脏移植受者中环孢素A的处置
Clin Transplant. 2016 Sep;30(9):1074-81. doi: 10.1111/ctr.12790. Epub 2016 Jul 11.
4
In linezolid underexposure, pharmacogenetics matters: The role of CYP3A5.在利奈唑胺剂量不足的情况下，药物遗传学很重要：CYP3A5 的作用。
Biomed Pharmacother. 2021 Jul;139:111631. doi: 10.1016/j.biopha.2021.111631. Epub 2021 Apr 30.
5
Modification of single-nucleotide polymorphism in a fully humanized CYP3A mouse by genome editing technology.通过基因组编辑技术修饰完全人源化 CYP3A 小鼠的单核苷酸多态性。
Sci Rep. 2017 Nov 9;7(1):15189. doi: 10.1038/s41598-017-15033-0.
6
The missing linkage: what pharmacogenetic associations are left to find in CYP3A?缺失的联系：CYP3A 中还有哪些药物遗传学关联有待发现？
Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):17-28. doi: 10.1517/17425250903379546.
7
Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.药物遗传学对南印度人群中他汀类药物诱发肌病的影响。
Indian Heart J. 2018 Dec;70 Suppl 3(Suppl 3):S120-S125. doi: 10.1016/j.ihj.2018.07.009. Epub 2018 Aug 10.
8
Association between cytochrome P450 3A5 polymorphism and the lung function in Saskatchewan grain workers.细胞色素P450 3A5基因多态性与萨斯喀彻温省谷物工人肺功能的关联。
Pharmacogenet Genomics. 2008 Jun;18(6):487-93. doi: 10.1097/FPC.0b013e3282fb02ba.
9
Individualized Tacrolimus Therapy for Pediatric Nephrotic Syndrome: Considerations for Ontogeny and Pharmacogenetics of CYP3A.儿童肾病综合征个体化他克莫司治疗：CYP3A 个体发育和药物遗传学的考虑因素。
Curr Pharm Des. 2018;24(24):2765-2773. doi: 10.2174/1381612824666180829101836.
10
The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells.CYP3A5和ABCB1常见基因变异在人近端肾小管细胞中的功能影响。
Mol Pharm. 2015 Mar 2;12(3):758-68. doi: 10.1021/mp500590s. Epub 2015 Jan 29.
引用本文的文献
1
Refining tacrolimus dosing through CYP3A5 pharmacogenetics in Taiwanese renal transplant recipients.通过CYP3A5药物遗传学优化台湾肾移植受者的他克莫司给药方案。
Ren Fail. 2025 Dec;47(1):2523567. doi: 10.1080/0886022X.2025.2523567. Epub 2025 Sep 11.
2
Analysis of Tacrolimus Clearance in Patients with Kidney Transplants from Romania.罗马尼亚肾移植患者他克莫司清除率分析。
Biomedicines. 2025 Jun 18;13(6):1501. doi: 10.3390/biomedicines13061501.
3
Lack of association between genetic variations in and blood pressure or hypertension risk in the UK biobank.英国生物银行中[具体基因]的基因变异与血压或高血压风险之间缺乏关联。 （注：原文中“in ”表述不完整，这里按常规推测补充了“[具体基因]”）
Front Genet. 2025 May 20;16:1490863. doi: 10.3389/fgene.2025.1490863. eCollection 2025.
4
Prevalence of Actionable Exposures to Pharmacogenetic Medications Among Solid Organ Transplant Recipients in a Population-Scale Biobank.群体规模生物样本库中实体器官移植受者对药物遗传学药物的可操作暴露率
J Pers Med. 2025 May 2;15(5):185. doi: 10.3390/jpm15050185.
5
Pharmacogenetic Evaluation of Hospitalized Patients Requiring Naloxone for Reversal of Acute Opioid Toxicity.需要纳洛酮逆转急性阿片类药物毒性的住院患者的药物遗传学评估。
Hosp Pharm. 2025 May 20:00185787251339360. doi: 10.1177/00185787251339360.
6
Challenging pharmacotherapy management of a psychotic disorder due to a delicate pharmacogenetic profile and drug-drug interactions: a case report and literature review.由于药物遗传学特征和药物相互作用复杂，导致精神障碍的药物治疗管理极具挑战性：病例报告及文献复习。
Croat Med J. 2024 Aug 31;65(4):383-395. doi: 10.3325/cmj.2024.65.383.
7
Impact of CYP3A5 Polymorphisms on Pediatric Asthma Outcomes.CYP3A5 多态性对儿科哮喘结局的影响。
Int J Mol Sci. 2024 Jun 14;25(12):6548. doi: 10.3390/ijms25126548.
8
Pharmacogenomics of Hypertension in Africa: Paving the Way for a Pharmacogenetic-Based Approach for the Treatment of Hypertension in Africans.非洲高血压的药物基因组学：为基于药物遗传学的非洲高血压治疗方法铺平道路。
Int J Hypertens. 2023 May 30;2023:9919677. doi: 10.1155/2023/9919677. eCollection 2023.
9
Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment in Austrian kidney transplant recipients participating in the U-PGx PREPARE study.奥地利参加 U-PGx PREPARE 研究的肾移植受者中，基于药物基因组学指导的他克莫司治疗的成本效用分析。
Pharmacogenomics J. 2024 Mar 18;24(2):10. doi: 10.1038/s41397-024-00330-5.
10
Evaluation of the usefulness of plasma 4β-hydroxycholesterol concentration normalized by 4α-hydroxycholesterol for accurate CYP3A phenotyping.通过4α-羟基胆固醇标准化的血浆4β-羟基胆固醇浓度用于准确的CYP3A表型分析的效用评估。
Clin Transl Sci. 2024 Mar;17(3):e13768. doi: 10.1111/cts.13768.
本文引用的文献
1
Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development.东亚人和欧洲人在药代动力学/药效学相关基因的主要功能多态性方面的人群差异：对新药开发临床试验的影响。
Drug Metab Pharmacokinet. 2012;27(1):9-54. doi: 10.2133/dmpk.dmpk-11-rv-111. Epub 2011 Nov 29.
2
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.单核苷酸多态性与一线舒尼替尼治疗晚期肾细胞癌患者的反应和毒性效应的相关性：一项多中心、观察性、前瞻性研究。
Lancet Oncol. 2011 Nov;12(12):1143-50. doi: 10.1016/S1470-2045(11)70266-2. Epub 2011 Oct 17.
3
Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension.CYP3A5 多态性（6986G>A）与血压和高血压的关联。
Hypertens Res. 2011 Nov;34(11):1216-20. doi: 10.1038/hr.2011.112. Epub 2011 Aug 4.
4
Dosing equation for tacrolimus using genetic variants and clinical factors.基于遗传变异和临床因素的他克莫司剂量方程。
Br J Clin Pharmacol. 2011 Dec;72(6):948-57. doi: 10.1111/j.1365-2125.2011.04039.x.
5
The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia.CYP3A5*3 对儿童急性淋巴细胞白血病风险和预后的影响。
Eur J Haematol. 2011 Jun;86(6):477-83. doi: 10.1111/j.1600-0609.2011.01608.x.
6
Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population.印度南部人群中药物代谢相 I 酶 CYP2E1、CYP2A6 和 CYP3A5 的遗传多态性。
Fundam Clin Pharmacol. 2012 Apr;26(2):295-306. doi: 10.1111/j.1472-8206.2010.00917.x. Epub 2011 Jan 25.
7
Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.CYP3A5 表达基因型低的急性淋巴细胞白血病患儿长春新碱神经毒性风险增加。
Pediatr Blood Cancer. 2011 Mar;56(3):361-7. doi: 10.1002/pbc.22845. Epub 2010 Nov 11.
8
Analysis of CYP3A5*3 and CYP3A5*6 gene polymorphisms in Indian chronic myeloid leukemia patients.印度慢性髓性白血病患者中CYP3A5*3和CYP3A5*6基因多态性分析
Asian Pac J Cancer Prev. 2010;11(3):781-4.
9
Optimization of initial tacrolimus dose using pharmacogenetic testing.基于遗传药理学检测的他克莫司初始剂量优化。
Clin Pharmacol Ther. 2010 Jun;87(6):721-6. doi: 10.1038/clpt.2010.17. Epub 2010 Apr 14.
10
Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.CYP3A 和 ABCB1 单核苷酸多态性对钙调神经磷酸酶抑制剂的药代动力学和药效学的影响：第一部分。
Clin Pharmacokinet. 2010 Mar;49(3):141-75. doi: 10.2165/11317350-000000000-00000.
Zotero 插件